Details of immunosuppressants, clinical responses and indications
| Findings, n (%) | Patients (n=202) | Indication | Stabilisation during the 7–12-month follow-up period | Clinical response during the 7–12-month follow-up period |
| Rituximab | 92 (45.5) | Neuropathy=73 (79.3) Haemopathy=1 (1.1) Both=18 (19.5) | 27 (29.3) | 29 (31.5) |
| Chlorambucil | 33 (16.3) | Neuropathy=27 (81.8) Both=5 (15.2) Not known= 1 | 8 (24.2) | 1 (3) |
| Chlorambucil Rituximab | 11 (5.4) | Neuropathy=5 (45.5) Haemopathy=1 (9.1) Both=5 (45.6) | 4 (36.4) | 4 (36.4) |
| Rituximab Dexamethasone Cyclophosphamide | 17 (8.4) | Neuropathy=5 (29.4) Haemopathy=2 (11.8) Both=10 (58.8) | 3 (17.6) | 3 (17.6) |
| Rituximab Cyclophosphamide Fludarabine | 8 (4) | Neuropathy=1 (12.5) Both=7 (87.5) | 0 | 2 (25) |
| Rituximab Fludarabine | 8 (4) | Neuropathy=4 (50) Haemopathy=2 (25) Both=2 (25) | 2 (25) | 3 (37.5) |
| Fludarabine | 4 (2) | Neuropathy=4 (100) | 0 | 0 |
Both indicates neuropathy and haemopathy.